Faulkner J K, Stopher D A, Walden R, Singleton W, Taylor S H
Eur J Clin Pharmacol. 1976 Feb 6;9(4):315-7. doi: 10.1007/BF00561666.
Bioavailability of capsule and tablet formulations of tolamolol were compared by measuring plasma concentration of tolamolol and reduction in maximum exercise heart rate over a period of twelve hours in eight healthy subjects in a two-way cross-over study. Tolamolol was absorbed more rapidly from capsules than from tablets; this did not result in any significant difference in the reduction in maximum exercise heart rate between the two formulations. There was no significant difference between area under curve of reduction in exercise tachycardia and area under-curve of plasma concentration of tolamolol for the two formulations. Reduction in maximum exercise heart rate was related to logarithm of plasma concentration of tolamolol between two and twelve hours after both formulations.
在一项双向交叉研究中,对8名健康受试者在12小时内测量托拉洛尔的血浆浓度和最大运动心率降低情况,比较了托拉洛尔胶囊和片剂剂型的生物利用度。托拉洛尔从胶囊中的吸收比从片剂中更快;但这两种剂型在最大运动心率降低方面没有任何显著差异。两种剂型在运动性心动过速降低曲线下面积和托拉洛尔血浆浓度曲线下面积之间没有显著差异。两种剂型服用后两到十二小时内,最大运动心率降低与托拉洛尔血浆浓度的对数相关。